We have a proven track record of success in drug discovery, drug development, FDA approval and commercialization.
President and Chief Executive Officer
Jerry McLaughlin has served as our President and Chief Executive Officer since June 2014. He has 25 years of executive, operational and commercial leadership experience in the biopharmaceutical industry. Prior to joining AgeneBio, he served as the Senior Vice President and Chief Commercial Officer of NuPathe Inc. until the company was acquired by Teva Pharmaceuticals Industries Ltd. in 2014. Mr. McLaughlin served in a variety of commercial leadership roles at Merck from 1990 to 2001 and Endo Pharmaceuticals from 2001 to 2007. He holds a BA in Economics from Dickinson College and an MBA from Villanova University.
Michela Gallagher, PhD
Founder and Scientific Advisor
Michela Gallagher, PhD, founded AgeneBio in 2008 and serves as a Scientific Advisor. Dr. Gallagher is the Krieger-Eisenhower Professor of Psychological and Brain Science and heads the Neurogenetics and Behavior Center at Johns Hopkins University. She is a Fellow of the American Psychological Association, the American Psychological Society and the American Association for the Advancement of Science. She has spent 20 years researching memory and learning as well as the neurobiology of aging, having published more than 250 peer-reviewed papers, and brings this expertise to the company as it seeks to advance discoveries to address amnestic mild cognitive impairment and Alzheimer’s disease. Dr. Gallagher is the 2014 recipient of the Society for Neuroscience, Mika Salpeter Lifetime Achievement Award and in 2010 received the American Psychological Association, D.O. Hebb Distinguished Scientific Contribution Award. She was also the recipient of a Senior Research Scientist Award from National Institute of Mental Health (1990-1999), a Freedom to Discover Award from the Bristol-Myers Foundation (2003-2008), and Senior Scientist Award from the Ellison Medical Foundation (2008-2012). She has served the on Boards of Scientific Counselors at the National Institute of Mental Health and the National Institute on Aging and currently serves on the Scientific Advisory Board of the Stanley Center at the Broad Institute. Prior to joining Johns Hopkins in 1997, Dr. Gallagher rose through the faculty ranks at University of North Carolina at Chapel Hill, where she was the Kenan Professor of Psychology. She earned her PhD in Physiological Psychology from University of Vermont.
Sharon Rosenzweig-Lipson, PhD
Vice President of Research and Development
Sharon Rosenzweig-Lipson, PhD, has served as our Vice President of Research and Development since 2011. Dr. Rosenzweig-Lipson offers AgeneBio expertise in screening strategies, in vivo models, translation and early clinical development strategy. She has more than 20 years of experience developing compounds for psychiatric and neurologic indications in the pharmaceutical industry, including American Cyanamid, American Home Products, Wyeth and Pfizer. She earned her PhD in Behavioral Neuroscience from Harvard University.
Richard Mohs, PhD
Vice President of Clinical Development
Richard Mohs, PhD, has served as our Vice President of Clinical Development since December 2015. Dr. Mohs offers more than 30 years of experience in neuroscience clinical development and led Eli Lilly’s Phase 3 development team for Alzheimer’s disease drug candidates solanezumab and semagacestat. He served as Eli Lilly’s Vice President for Neuroscience Early Clinical Development and Distinguished Research Fellow within Lilly Research Laboratories, where he led a clinical development team targeting Alzheimer’s disease or other neurodegenerative diseases, pain, depression or schizophrenia. Previously, he was Professor in the Department of Psychiatry with the Mount Sinai School of Medicine and Associate Chief of Staff for Research at the Bronx Veterans Affairs Medical Center. During this time, he was instrumental in designing clinical trials that led to the approval in the US and other countries of cholinergic drug treatments for Alzheimer’s disease. Dr. Mohs has served as an advisor to many neuroscience research programs at universities in the United States and to several foundations supporting neuroscience research including the John D. and Catherine T. MacArthur Foundation, the Charles A. Dana Foundation and has recently been appointed to the Board of Governors for the Alzheimer’s Drug Discovery Foundation. Dr. Mohs received his PhD in psychology from Stanford University and completed postdoctoral training in pharmacology at the Stanford University Medical School.
Director of Business Operations
Sarita Foster has served as our Director of Business Operations since June 2014. Sarita offers more than 25 years of experience in accounting and finance. Prior to joining AgeneBio, she served in senior finance positions for more than 10 years at Johns Hopkins University, most recently as Assistant Dean, Financial Operations at the Zanvyl Krieger School of Arts and Sciences. Previously, she served as Controller for Martin Marietta Laboratories. She earned an MBA from Loyola University and a BS from the University of Virginia and is licensed as a non-practicing CPA.